Cite
CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
MLA
Rydström, Karin, et al. “CD40 Is a Potential Marker of Favorable Prognosis in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy.” Leukemia & Lymphoma, vol. 51, no. 9, Sept. 2010, pp. 1643–48. EBSCOhost, https://doi.org/10.3109/10428194.2010.492537.
APA
Rydström, K., Linderoth, J., Nyman, H., Ehinger, M., Joost, P., Bendahl, P.-O., Leppä, S., & Jerkeman, M. (2010). CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leukemia & Lymphoma, 51(9), 1643–1648. https://doi.org/10.3109/10428194.2010.492537
Chicago
Rydström, Karin, Johan Linderoth, Heidi Nyman, Mats Ehinger, Patrick Joost, Pär-Ola Bendahl, Sirpa Leppä, and Mats Jerkeman. 2010. “CD40 Is a Potential Marker of Favorable Prognosis in Patients with Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy.” Leukemia & Lymphoma 51 (9): 1643–48. doi:10.3109/10428194.2010.492537.